Table 3.

Multinomial logistic regression for predictors of class membership (N = 187)

	Reference: Resilient						Ref: Moderate symptoms
	Elevated symptoms			Moderate symptoms			Elevated symptoms
Variable	OR	95% CI	P	OR	95% CI	P	OR	95% CI	P
Age	0.94	[0.89–0.99]	.02	0.98	[0.93–1.03]	.474	0.95	[0.91–1.00]	.046
BMI, Current	1.18	[1.06–1.3]	.002	0.99	[0.91–1.08]	.888	1.18	[1.05–1.33]	.004
Education (College+)	2.04	[0.32–13.16]	.452	1.19	[0.27–5.23]	.813	1.71	[0.33–8.86]	.522
Race (Caucasian)	0.26	[0.04–1.82]	.176	2.10	[0.52–8.49]	.299	0.13	[0.02–0.83]	.031
Household income (>$70k)	0.52	[0.13–2.09]	.357	0.45	[0.14–1.5]	.195	1.14	[0.32–4.12]	.836
Family history of cancer	0.10	[0.02–0.37]	.001	0.94	[0.38–2.32]	.886	0.10	[0.03–0.39]	.001
Medications:
Tamoxifen	0.27	[0.07–1.08]	.064	0.59	[0.23–1.48]	.26	0.46	[0.1–2.05]	.308
Letrozole	0.23	[0.05–1.13]	.07	1.24	[0.48–3.23]	.652	0.19	[0.03–0.99]	.048
Cancer med.	1.14	[0.35–3.76]	.828	1.86	[0.72–4.81]	.198	0.61	[0.16–2.3]	.469
Psychotropic med.	9.02	[1.69–47.98]	.01	5.79	[1.99–16.88]	.001	1.56	[0.32–7.6]	.583
Treatment:
Cancer stage	1.04	[.48–2.23]	.925	1.36	[0.75–2.46]	.314	.76	[0.35–1.65]	.496
Received chemotherapy	3.29	[1.16–9.29]	.025	2.51	[1.05–6.03]	.039	1.31	[0.43–3.99]	.639
Months since diagnosis	.00	[0.00–0.15]	.009	.48	[0.03–8.01]	.608	.00	[0.00–0.30]	.018
BMI, loss (pre/post treatment)	1.80	[0.7–4.63]	.220	1.43	[0.66–3.08]	.361	1.26	[0.47–3.38]	.644

Ref reference class, OR odds ratio, 95% CI 95% confidence interval, Med. medication, BMI body mass index